|
|
|
|
Acromegaly Medical and Health News Headlines
|
|
|
|
|
|
|
All Recent Acromegaly Medical Condition News Headlines |
|
|
|
|
Adverse anthropometric risk profile in biochemically controlled acromegalic patients: comparison with an age- and gender-matched primary care population
Abstract GH and IGF-1 play an important role in the regulation of metabolism and body composition. In patients with uncontrolled acromegaly,
cardiovascular morbidity and mortality are increased but are supposed to be normalised after biochemical control is achieved.
We aimed at comparing body composition and the cardiovascular risk profile in patients with controlled acromegaly and controls.
A cross-sectional study. We evaluated anthropometric parameters (height, weight, body mass index (BMI), waist and hip circumference,
waist to height ratio) and, additionally, cardiovascular risk biomarkers (fasting plasma glucose, HbA1c, triglycerides, total
cholesterol, HDL, LDL, and lipoprotein (a), in 81 acromegalic patients (58% cured) compared to 320 age- and gender-matched
contro......
POSTED 02/03/2010 at 11:59 AM --
|
Growth Hormone Administration: Is It Safe and Effective for Athletic Performance
Human growth hormone (GH) is widely abused by athletes; however, there is little evidence that GH improves physical performance. Replacement of GH in GH deficiency improves some aspects of exercise capacity. There is evidence for a protein anabolic effect of GH in healthy adults and for increased lean body mass following GH, although fluid retention likely contributes to this increase. The evidence suggests that muscle strength, power, and aerobic exercise capacity are not enhanced by GH administration, however GH may improve anaerobic exercise capacity. There are risks of adverse effects of long-term abuse of GH. Sustained abuse of GH may lead to a state mimicking acromegaly, a condition with increased morbidity and mortality. (Source: Endocrinology and Metabolism Clinics of North America......
POSTED 01/19/2010 at 08:14 AM --
|
Mortality in Patients with Pituitary Disease.
Authors: Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS, Stewart PM
Pituitary disease is associated with increased mortality predominantly due to vascular disease. Control of cortisol secretion and GH hypersecretion (and cardiovascular risk factor reduction) is key in the reduction of mortality in patients with Cushing's disease and acromegaly, retrospectively. For patients with acromegaly, the role of IGF-I is less clear-cut. Confounding pituitary hormone deficiencies such as gonadotropins and particularly ACTH deficiency (with higher doses of hydrocortisone replacement) may have a detrimental effect on outcome in patients with pituitary disease. Pituitary radiotherapy is a further factor that has been associated with increased mortality (particul......
POSTED 01/18/2010 at 06:00 PM --
|
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
CONCLUSION: Cabergoline, typically dosed for the long-term treatment of hyperprolactinemia or acromegaly, appears not to be associated with an increased risk of fibrotic adverse events.
PMID: 20071478 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)...
POSTED 01/12/2010 at 06:00 PM --
|
Endocrine Aspects of Obstructive Sleep Apnea.
Conclusions: Given the potential neurocognitive consequences and increased cardiovascular risk associated with OSA, specific therapy such as continuous positive airway pressure is recommended if OSA persists despite effective treatment of its potential endocrine and metabolic causes.
PMID: 20061419 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)...
POSTED 01/07/2010 at 06:00 PM --
|
Is acromegaly under-diagnosed?
Historically, acromegaly has been under-recognised until its later stages when clinical characteristics are more apparent but treatment is more difficult. Reid et al. examined data from 324 patients presenting with acromegaly from 1981 to 2006 and found that signs, symptoms and associated comorbidities, tumour size and preoperative GH levels did not change significantly in the 26 years since the patients were diagnosed, indicating that their acromegaly was already advanced at diagnosis. The authors conclude that clinical recognition of acromegaly has not improved much in the last 25 years and that increased awareness of acromegaly amongst practitioners is required. Reid et al., Clinical Endocrinology, DOI: 10.1111/j.1365-2265.2009.03626.x (Source: Society for Endocrinology)...
POSTED 01/05/2010 at 06:00 AM --
|
A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
CONCLUSION: Our findings provide support for the long-term safety and efficacy of the GH receptor antagonist pegvisomant in achieving IGF-I control in patients with refractory acromegaly.
PMID: 20003832 [PubMed - in process] (Source: Clinical and Investigative Medicine)...
POSTED 12/19/2009 at 09:54 AM --
|
Development of a Disease-Specific Quality of Life Questionnaire in Addison's Disease.
Conclusions: We envisage AddiQoL having utility in trials of hormone replacement and management of patients with Addison's disease, analogous to similar questionnaires in GH deficiency (AGHDA) and acromegaly (AcroQoL).
PMID: 20016050 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)...
POSTED 12/15/2009 at 06:00 PM --
|
Body size variation in insects: a macroecological perspective
Body size is a key feature of organisms and varies continuously because of the effects of natural selection on the size-dependency of resource acquisition and mortality rates. This review provides a critical and synthetic overview of body size variation in insects from a predominantly macroecological (large-scale temporal and spatial) perspective. Because of the importance of understanding the proximate determinants of adult size, it commences with a brief summary of the physiological mechanisms underlying adult body size and its variation, based mostly on findings for the model species Drosophila melanogaster and Manduca sexta. Variation in nutrition and temperature have variable effects on critical weight, the interval to cessation of growth (or terminal growth period) and growth rates, ......
POSTED 12/10/2009 at 06:00 PM --
|
Hemostatic and Fibrinolytic Abnormalities in Endocrine Diseases: A Narrative Review
Semin Thromb Hemost 2009; 35: 605-612DOI: 10.1055/s-0029-1242714ABSTRACTThis review summarizes current knowledge of the effects of polycystic ovary syndrome, Cushing's syndrome, thyrotoxicosis, hypothyroidism, primary hyperparathyroidism, acromegaly, hypopituitarism, and growth hormone deficiency on coagulation and fibrinolysis. Several abnormalities of the coagulation-fibrinolytic system have been described among patients affected by these endocrine disorders. Although further larger studies are needed to provide more definitive information, clinically overt hypothyroidism appears to be associated with a bleeding tendency, whereas all other endocrine diseases appear to be associated with a thrombotic tendency. The disorders of coagulation and fibrinolysis observed in these endocrine patho......
POSTED 12/10/2009 at 08:19 AM --
|
Body size variation in insects: a macroecological perspective.
Authors: Chown SL, Gaston KJ
Body size is a key feature of organisms and varies continuously because of the effects of natural selection on the size-dependency of resource acquisition and mortality rates. This review provides a critical and synthetic overview of body size variation in insects from a predominantly macroecological (large-scale temporal and spatial) perspective. Because of the importance of understanding the proximate determinants of adult size, it commences with a brief summary of the physiological mechanisms underlying adult body size and its variation, based mostly on findings for the model species Drosophila melanogaster and Manduca sexta. Variation in nutrition and temperature have variable effects on critical weight, the interval to cessation of growth (or terminal ......
POSTED 12/09/2009 at 06:00 PM --
|
Tumor Volume of Growth Hormone-Secreting Pituitary Adenomas during Treatment with Pegvisomant: A Prospective Multicenter Study.
Conclusions: This study shows that pegvisomant therapy infrequently coincides with tumor growth during long-term treatment of acromegaly. Because all significant tumor volume increases occurred during the first year, these changes might correlate to the change of medication and thus be the result of a rebound from somatostatin-induced shrinkage.
PMID: 19965922 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)...
POSTED 12/03/2009 at 06:00 PM --
|
Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1)
We report phenocopies in Multiple Endocrine Neoplasia type 1 (MEN1), an autosomal dominant disorder, characterised by the combined occurrence of parathyroid, pituitary and pancreatic tumours. We studied 261 affected individuals from 74 families referred with a clinical diagnosis of MEN1 and sought inconsistencies between the mutational and clinical data. We identified four patients from unrelated families with phenocopies. Patients 1 and 2 from families with MEN1, developed prolactinomas as the sole endocrinopathy but they did not harbour the germlineMEN1 mutation present in their affected relatives. Patient 3, had acromegaly and recurrent hypercalcaemia following parathyroidectomy, whilst patient 4 had parathyroid tumours and a microprolactinoma. Patients 3 and 4 and their relatives did n......
POSTED 11/30/2009 at 06:00 PM --
|
A complex case of Multiple Endocrine Neoplasia type 1 with Metastatic Parathyroid Carcinoma
We describe below a patient with Multiple Endocrine Neoplasia type 1 (MEN type 1) who presented with features of Primary Hyperparathyroidism.
However, the actual diagnosis of Parathyroid Carcinoma was delayed until metastases to the lung were discovered. She was also
found to have Pituitary Macro adenoma with Silent Acromegaly, with no clinical features whatsoever. She underwent transphenoidal
hypophysectomy with postoperative radiotherapy. However, the disease process remained biochemically active necessitating commencement
of somatostatin analogues. There is also a tumour at the head of the pancreas which at present is non functional with normal
gut hormone profile and normal 24 hour urinary 5-hydroxyl indole acetic acid (5-HIAA) excretion assay. Our case highlights
the pitfalls in......
POSTED 11/25/2009 at 11:02 AM --
|
Pregnancy and pituitary disorders.
Authors: Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F
Major hormonal changes emerge during pregnancy. The pituitary gland is one of the most affected organs with altered anatomy and physiology. The pituitary gland is enlarged as a result of lactotroph hyperplasia. Due to physiological changes in the pituitary and target hormone levels, binding globulins and placental hormones, hormonal evaluation becomes more complex in pregnant women. As a consequence of physiological hormonal changes, the evaluation of pituitary functions in pregnant women is quite different from the prepregnant state. Pituitary adenomas may cause problems by their hormone secretion that affect the mother and the fetus besides causing an increased risk of tumour growth. Furthermore, diagnosis, course and treat......
POSTED 11/23/2009 at 06:00 PM --
|
Invitation for Basic Science and Clinical Cases - SfE BES 2010
New for SfE BES 2010 - Invitation for basic science cases
For SfE BES 2010, the Society is introducing a number of Basic Science Meet the Expert sessions. These will be relatively informal sessions with discussion based around new basic science technologies. If you would like to submit a specific issue to be discussed by the experts, please send a synopsis of the issue in a Word document (max. 300 words) to: conferences@endocrinology.org. The Basic Science Meet the Expert sessions will include: Metabolomics:challenges and rewards of deciphering the metabolome in diabetes and obesity; Resources in bioinformatics-How can it help your research?; and Mutagenesis resources - How to get your knock out mouse cheap and quick. The deadline for submissions is 18 January 2010.
Invitation for Clinic......
POSTED 11/20/2009 at 06:00 AM --
|
[Management of acromegaly in pregnant woman.]
We report the case of a 26-year-old woman with a GH-secreting pituitary macroadenoma who was operated by transphenoidal approach. After surgery, she had a persistant acromegaly due to an intrasellar tumour. She was treated by lanreotide. After one year, the patient had married and became pregnant. Lanreotide was stopped when the diagnosis of pregnancy was established. The follow-up of this patient showed a progressive increase of IGF1 level during pregnancy without tumoral syndrome or visual troubles. No metabolic complication was detected. The patient went to term and gave birth to a healthy baby. In postpartum, the IGF1 level was normal, but the brain MRI revealed a 10mm intrasellar tumour. The pituitary adenoma was not significantly enlarged during pregnancy. Therefore, pregnancy doesn'......
POSTED 11/16/2009 at 06:00 PM --
|
Acromegaly
(Source: eMedicineHealth.com)...
POSTED 11/16/2009 at 01:00 AM --
|
Focal Neuronal Gigantism: A Rare Complication of Therapeutic Radiation [BRAIN]
We report this rare delayed complication in a patient following treatment of a right frontal anaplastic oligodendroglioma. (Source: American Journal of Neuroradiology)...
POSTED 11/13/2009 at 12:02 PM --
|
Aftercare in patients with Cushing’s disease and acromegaly: is there room for improvement?
Conclusions The postoperative transfer back to the endocrinologist after operative treatment is achieved well in both groups. In uncured
AC, medical therapy is initiated early, but options of therapy offer room for improvement. Therapy of recurrence is delayed
in both pathologies.
Content Type Journal ArticleCategory Clinical ArticleDOI 10.1007/s00701-009-0544-6Authors
Tsambika Psaras, University of Tuebingen Department of Neurosurgery Hoppe-Seyler-Strasse 3 72076 Tuebingen GermanyMonika Milian, University of Tuebingen Department of Neurosurgery Hoppe-Seyler-Strasse 3 72076 Tuebingen GermanyValerie Hattermann, University of Tuebingen Department of Neurosurgery Hoppe-Seyler-Strasse 3 72076 Tuebingen GermanyBaptist Gallwitz, University of Tuebingen Department of Endocri......
POSTED 11/12/2009 at 01:01 PM --
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE:
The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
